FDA
-
-
-
-
-
-
-
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
-
-
-
-
-
-
-
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
-
-
-
-
-
-
-
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at Leerink Partners
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird
-
-
-
-
-
-
-
Biohaven receives FDA update on troriluzole drug application
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
326,424 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

